New Alport Patient Registry Now Enrolling
All Alport patients residing in the U.S. are encouraged to enroll today.
re: FDA Decision on Bardoxolone Methyl
February 25, 2022 On February 25th, the U.S. Food and Drug Administration (FDA) announced its decision not to approve a New Drug Application for the use of bardoxolone methyl as a treatment for Alport syndrome. Bardoxolone methyl was investigated for safety and efficacy in Alport patients through the CARDINAL Study, the first-ever clinical trial […]
